|
1
|
Brenner H, Kloor M and Pox CP: Colorectal
cancer. Lancet. 383:1490–1502. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Tran NH, Cavalcante LL, Lubner SJ,
Mulkerin DL, LoConte NK, Clipson L, Matkowskyj KA and Deming DA:
Precision medicine in colorectal cancer: The molecular profile
alters treatment strategies. Ther Adv Med Oncol. 7:252–262. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Brenner H, Bouvier AM, Foschi R, Hackl M,
Larsen IK, Lemmens V, Mangone L and Francisci S: EUROCARE Working
Group: Progress in colorectal cancer survival in Europe from the
late 1980s to the early 21st century: The EUROCARE study. Int J
Cancer. 131:1649–1658. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Sankaranarayanan R, Swaminathan R, Brenner
H, Chen K, Chia KS, Chen JG, Law SC, Ahn YO, Xiang YB, Yeole BB, et
al: Cancer survival in Africa, Asia, and Central America: A
population-based study. Lancet Oncol. 11:165–173. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Wang X, Tanaka M, Krstin S, Peixoto HS,
Moura CC and Wink M: Cytoskeletal interference - A new mode of
action for the anticancer drugs camptothecin and topotecan. Eur J
Pharmacol. 789:265–274. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Song XL, Liu S, Jiang Y, Gu LY, Xiao Y,
Wang X, Cheng L and Li XT: Targeting vincristine plus tetrandrine
liposomes modified with DSPE-PEG2000-transferrin in treatment of
brain glioma. Eur J Pharm Sci. 96:129–140. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Noh JK, Naeem M, Cao J, Lee EH, Kim MS,
Jung Y and Yoo JW: Herceptin-functionalized pure paclitaxel
nanocrystals for enhanced delivery to HER2-postive breast cancer
cells. Int J Pharm. 513:543–553. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Frémont L: Biological effects of
resveratrol. Life Sci. 66:663–673. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Orallo F: Comparative studies of the
antioxidant effects of cis- and trans-resveratrol. Curr Med Chem.
13:87–98. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Zhu M, Zhang Q, Wang X, Kang L, Yang Y,
Liu Y, Yang L, Li J, Yang L, Liu J, et al: Metformin potentiates
anti-tumor effect of resveratrol on pancreatic cancer by
down-regulation of VEGF-B signaling pathway. Oncotarget.
7:84190–84200. 2016.PubMed/NCBI
|
|
11
|
Chin YT, Hsieh MT, Yang SH, Tsai PW, Wang
SH, Wang CC, Lee YS, Cheng GY, HuangFu WC, London D, et al:
Anti-proliferative and gene expression actions of resveratrol in
breast cancer cells in vitro. Oncotarget. 5:12891–12907. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Liu YZ, Wu K, Huang J, Liu Y, Wang X, Meng
ZJ, Yuan SX, Wang DX, Luo JY, Zuo GW, et al: The PTEN/PI3K/Akt and
Wnt/β-catenin signaling pathways are involved in the inhibitory
effect of resveratrol on human colon cancer cell proliferation. Int
J Oncol. 45:104–112. 2014.PubMed/NCBI
|
|
13
|
Bragdon B, Moseychuk O, Saldanha S, King
D, Julian J and Nohe A: Bone morphogenetic proteins: A critical
review. Cell Signal. 23:609–620. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Zhang L, Ye Y, Long X, Xiao P, Ren X and
Yu J: BMP signaling and its paradoxical effects in tumorigenesis
and dissemination. Oncotarget. 7:78206–78218. 2016.PubMed/NCBI
|
|
15
|
Herrera B, García-Álvaro M, Cruz S, Walsh
P, Fernández M, Roncero C, Fabregat I, Sánchez A and Inman GJ: BMP9
is a proliferative and survival factor for human hepatocellular
carcinoma cells. PLoS One. 8:e695352013. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Peng J, Yoshioka Y, Mandai M, Matsumura N,
Baba T, Yamaguchi K, Hamanishi J, Kharma B, Murakami R, Abiko K, et
al: The BMP signaling pathway leads to enhanced proliferation in
serous ovarian cancer-A potential therapeutic target. Mol Carcinog.
55:335–345. 2016. View
Article : Google Scholar : PubMed/NCBI
|
|
17
|
Wang L, Park P, Zhang H, La Marca F,
Claeson A, Valdivia J and Lin CY: BMP-2 inhibits the tumorigenicity
of cancer stem cells in human osteosarcoma OS99-1 cell line. Cancer
Biol Ther. 11:457–463. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Ying X, Sun Y and He P: Bone morphogenetic
protein-7 inhibits EMT-associated genes in breast cancer. Cell
Physiol Biochem. 37:1271–1278. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Ren CM, Li Y, Chen QZ, Zeng YH, Shao Y, Wu
QX, Yuan SX, Yang JQ, Yu Y, Wu K, et al: Oridonin inhibits the
proliferation of human colon cancer cells by upregulating BMP7 to
activate p38 MAPK. Oncol Rep. 35:2691–2698. 2016.PubMed/NCBI
|
|
20
|
Cassar L, Nicholls C, Pinto AR, Chen R,
Wang L, Li H and Liu JP: TGF-beta receptor mediated telomerase
inhibition, telomere shortening and breast cancer cell senescence.
Protein Cell. 8:39–54. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Leinhäuser I, Richter A, Lee M, Höfig I,
Anastasov N, Fend F, Ercolino T, Mannelli M, Gimenez-Roqueplo AP,
Robledo M, et al: Oncogenic features of the bone morphogenic
protein 7 (BMP7) in pheochromocytoma. Oncotarget. 6:39111–39126.
2015.PubMed/NCBI
|
|
22
|
Fresno Vara JA, Casado E, De Castro J,
Cejas P, Belda-Iniesta C and González-Barón M: PI3K/Akt signalling
pathway and cancer. Cancer Treat Rev. 30:193–204. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Luo J, Deng ZL, Luo X, Tang N, Song WX,
Chen J, Sharff KA, Luu HH, Haydon RC, Kinzler KW, et al: A protocol
for rapid generation of recombinant adenoviruses using the AdEasy
system. Nat Protoc. 2:1236–1247. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Tate CM, Mc Entire J, Pallini R, Vakana E,
Wyss L, Blosser W, Ricci-Vitiani L, D'Alessandris QG, Morgante L,
Giannetti S, et al: A BMP7 variant inhibits tumor angiogenesis in
vitro and in vivo through direct modulation of endothelial cell
biology. PLoS One. 10:e01256972015. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Mendes RD, Canté-Barrett K, Pieters R and
Meijerink JP: The relevance of PTEN-AKT in relation to
NOTCH1-directed treatment strategies in T-cell acute lymphoblastic
leukemia. Haematologica. 101:1010–1017. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Shen M, Jia GL, Wang YM and Ma H:
Cardioprotective effect of resvaratrol pretreatment on myocardial
ischemia-reperfusion induced injury in rats. Vascul Pharmacol.
45:122–126. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Lin KH, Hsiao G, Shih CM, Chou DS and Sheu
JR: Mechanisms of resveratrol-induced platelet apoptosis.
Cardiovasc Res. 83:575–585. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Valdecantos MP, Pérez-Matute P, Quintero P
and Martínez JA: Vitamin C, resveratrol and lipoic acid actions on
isolated rat liver mitochondria: All antioxidants but different.
Redox Rep. 15:207–216. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
de la Lastra CA and Villegas I:
Resveratrol as an antioxidant and pro-oxidant agent: Mechanisms and
clinical implications. Biochem Soc Trans. 35:1156–1160. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Sadi G, Bozan D and Yildiz HB: Redox
regulation of antioxidant enzymes: Post-translational modulation of
catalase and glutathione peroxidase activity by resveratrol in
diabetic rat liver. Mol Cell Biochem. 393:111–122. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Varoni EM, Lo Faro AF, Sharifi-Rad J and
Iriti M: Anticancer molecular mechanisms of resveratrol. Front
Nutr. 3:82016. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Bickenbach KA, Veerapong J, Shao MY,
Mauceri HJ, Posner MC, Kron SJ and Weichselbaum RR: Resveratrol is
an effective inducer of CArG-driven TNF-alpha gene therapy. Cancer
Gene Ther. 15:133–139. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Yuan SX, Wang DX, Wu QX, Ren CM, Li Y,
Chen QZ, Zeng YH, Shao Y, Yang JQ, Bai Y, et al: BMP9/p38 MAPK is
essential for the antiproliferative effect of resveratrol on human
colon cancer. Oncol Rep. 35:939–947. 2016.PubMed/NCBI
|
|
34
|
Ali IH and Brazil DP: Bone morphogenetic
proteins and their antagonists: current and emerging clinical uses.
Br J Pharmacol. 171:3620–3632. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Hu F, Zhang Y, Li M, Zhao L, Chen J, Yang
S and Zhang X: BMP-6 inhibits the metastasis of MDA-MB-231 breast
cancer cells by regulating MMP-1 expression. Oncol Rep.
35:1823–1830. 2016.PubMed/NCBI
|
|
36
|
Ortuño MJ, Ruiz-Gaspà S,
Rodríguez-Carballo E, Susperregui AR, Bartrons R, Rosa JL and
Ventura F: p38 regulates expression of osteoblast-specific genes by
phosphorylation of osterix. J Biol Chem. 285:31985–31994. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Sánchez-Duffhues G, Hiepen C, Knaus P and
Ten Dijke P: Bone morphogenetic protein signaling in bone
homeostasis. Bone. 80:43–59. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Tang Y, Xie H, Chen J, Geng L, Chen H, Li
X, Hou Y, Lu L, Shi S, Zeng X, et al: Activated NF-κB in bone
marrow mesenchymal stem cells from systemic lupus erythematosus
patients inhibits osteogenic differentiation through downregulating
Smad signaling. Stem Cells Dev. 22:668–678. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Mundi PS, Sachdev J, McCourt C and
Kalinsky K: AKT in cancer: New molecular insights and advances in
drug development. Br J Clin Pharmacol. 82:943–956. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Wang Z and Guo J: Mechanical induction of
BMP-7 in osteocyte blocks glucocorticoid-induced apoptosis through
PI3K/AKT/GSK3β pathway. Cell Biochem Biophys. 67:567–574. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Mayer IA and Arteaga CL: The PI3K/AKT
pathway as a target for cancer treatment. Annu Rev Med. 67:11–28.
2016. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Carnero A and Paramio JM: The
PTEN/PI3K/AKT pathway in vivo, cancer mouse models. Front Oncol.
4:2522014. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Hixon ML, Paccagnella L, Millham R,
Perez-Olle R and Gualberto A: Development of inhibitors of the
IGF-IR/PI3K/Akt/mTOR pathway. Rev Recent Clin Trials. 5:189–208.
2010. View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Milella M, Falcone I, Conciatori F, Incani
U Cesta, Del Curatolo A, Inzerilli N, Nuzzo CM, Vaccaro V, Vari S,
Cognetti F, et al: PTEN: Multiple functions in human malignant
tumors. Front Oncol. 5:242015. View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Leipert J, Kässner F, Schuster S, Händel
N, Körner A, Kiess W and Garten A: Resveratrol potentiates growth
inhibitory effects of rapamycin in PTEN-deficient lipoma cells by
suppressing p70S6 kinase activity. Nutr Cancer. 68:342–349. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Jing X, Cheng W, Wang S, Li P and He L:
Resveratrol induces cell cycle arrest in human gastric cancer
MGC803 cells via the PTEN-regulated PI3K/Akt signaling pathway.
Oncol Rep. 35:472–478. 2016.PubMed/NCBI
|
|
47
|
Wang G, Dai F, Yu K, Jia Z, Zhang A, Huang
Q, Kang C, Jiang H and Pu P: Resveratrol inhibits glioma cell
growth via targeting oncogenic microRNAs and multiple signaling
pathways. Int J Oncol. 46:1739–1747. 2015.PubMed/NCBI
|
